Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract Background: Locally advanced thyroid cancer involving critical cervical structures is often not amenable to upfront surgery, and effective strategies are needed to improve surgical feasibility. ALTER-T001 study evaluated the safety, efficacy, and quality of life (QoL) of neoadjuvant anlotinib in this setting. Methods: Patients with pathologically confirmed, locally advanced thyroid cancer not amenable to surgery received neoadjuvant anlotinib.
Papillary thyroid cancer (PTC) has an exceptional favorable prognosis, with a 20-year overall survival rate exceeding 90%, even reaching 95% for papillary thyroid microcarcinoma. This excellent prognosis has prompted the exploration of more conservative management strategies beyond surgery, such as active surveillance and thermal ablation.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.